My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Kenvue Inc. Common Stock (NY:KVUE)

17.18 -0.10 (-0.56%)

Streaming Delayed Price Updated: 11:55 AM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kenvue Inc. Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

25 26 Next >

Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months. ↗

December 04, 2024

These three dividend-paying companies have all raised their payouts every year for at least 40 consecutive years.

Via The Motley Fool

Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

November 25, 2024

From Kenvue

Via Business Wire

How Is The Market Feeling About Kenvue? ↗

November 20, 2024

Via Benzinga

In-Depth Technical Analysis of KENVUE INC. ↗

November 18, 2024

With a solid technical rating of 8 out of 10, KENVUE INC (NYSE:KVUE) is showing strong indications of a possible breakout.

Via Chartmill

FDA Wants To Pull Popular OTC Decongestant Used For Common Cold Over Effectiveness Concerns ↗

November 08, 2024

FDA proposes removing oral phenylephrine from OTC drugs for nasal congestion, citing ineffectiveness. Public comments open before a final order is issued.

Via Benzinga

Is Kenvue Stock a Buy Now? ↗

October 25, 2024

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

Via The Motley Fool

10 Analysts Have This To Say About Kenvue ↗

October 22, 2024

Via Benzinga

Navigating 10 Analyst Ratings For Kenvue ↗

October 11, 2024

Via Benzinga

Kenvue (KVUE) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

KVUE earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales ↗

November 07, 2024

Kenvue reports Q3 sales of $3.89 billion, slightly missing estimates. Strong growth in Essential Health offsets declines in Skin Health and Beauty.

Via Benzinga

Kenvue Reports Third Quarter 2024 Results

November 07, 2024

From Kenvue

Via Business Wire

Neutrogena® Launches Breakthrough Collaboration with Two of World’s Most Recognizable Dermatologists

October 31, 2024

From Kenvue

Via Business Wire

This Big New Development Could Be Bullish for Kenvue Stock ↗

October 30, 2024

Can tinkering around the edges actually make this stock more attractive?

Via The Motley Fool

P/E Ratio Insights for Kenvue ↗

September 27, 2024

Via Benzinga

3 Dividend Stocks to Double Up on Right Now ↗

October 27, 2024

While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.

Via The Motley Fool

Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy. ↗

October 26, 2024

Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.

Via The Motley Fool

Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months ↗

October 26, 2024

An activist investor is taking a stake in Kenvue stock.

Via The Motley Fool

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises ↗

October 22, 2024

The activist investor says Pfizer has underperformed its peers and the broader market since 2019.

Via Investor's Business Daily

Nvidia Among Five Best S&P 500 Stocks Today ↗

October 21, 2024

Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind.

Via Investor's Business Daily

Topics Stocks

Dow Drops 320 Points as Stocks Cool Off ↗

October 21, 2024

Stocks are stumbling out of the gate this week.

Via Talk Markets

Topics Stocks

What's Going On With Kenvue Stock Monday? ↗

October 21, 2024

Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.

Via Benzinga

Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday? ↗

October 21, 2024

U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the...

Via Benzinga

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies ↗

October 21, 2024

Elf Beauty appeared to rally along with KVUE on Monday.

Via Investor's Business Daily

Topics Stocks

Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump ↗

October 21, 2024

Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.

Via Talk Markets

Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff? ↗

October 20, 2024

Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc, the company behind popular consumer products like Tylenol and Listerine.

Via Benzinga

Kenvue to Announce Third Quarter 2024 Results on November 7, 2024

October 18, 2024

From Kenvue

Via Business Wire

Kenvue Declares Quarterly Cash Dividend

October 17, 2024

From Kenvue

Via Business Wire

Johnson & Johnson Stock: Setting the Stage for 2025 Highs

October 16, 2024

Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026.

Via MarketBeat

All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year ↗

October 13, 2024

Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.

Via The Motley Fool

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗

October 11, 2024

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.